Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ofirnoflast - Halia Therapeutics

Next Previous
Drug Profile

Ofirnoflast - Halia Therapeutics

Alternative Names: HT 6184

Latest Information Update: 11 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Halia Therapeutics
  • Class Amides; Amines; Analgesics; Aniline compounds; Anti-inflammatories; Antianaemics; Antidementias; Antineoplastics; Cyclopropanes; Eye disorder therapies; Fluorinated hydrocarbons; Fluorobenzenes; Isoxazoles; Obesity therapies; Pyrimidines; Pyrroles; Small molecules; Urea compounds
  • Mechanism of Action NEK7 protein inhibitors; NLRP3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Inflammatory pain; Myelodysplastic syndromes; Obesity
  • Preclinical Acute myeloid leukaemia; Eye disorders; Haemolytic anaemia
  • Research Alzheimer's disease
  • No development reported Inflammation

Most Recent Events

  • 31 Jul 2026 Halia Therapeutics plans a phase-II trial for Myelodysplastic syndromes (Treatment-experienced) in October 2026 (PO) (NCT07738510)
  • 15 Jun 2026 Ofirnoflast receives Fast Track designation for Myelodysplastic syndromes [PO] in USA
  • 12 May 2026 Efficacy and adverse events data from a phase IIa trial in Myelodysplastic syndromes released by Halia Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top